$PTX, StockNewsNow.com Publishes May 2016 Updat
Post# of 22755
Posted On: 05/17/2016 8:46:28 AM
$PTX,
StockNewsNow.com Publishes May 2016 Update SNNLive Video Interview with Provectus Biopharmaceuticals, Inc.
50 minutes ago - DJNF
LOS ANGELES, May 17, 2016 /PRNewswire/ -- StockNewsNow.com, The Official MicroCap News Source(TM), today published an SNNLive Video Interview with Peter R. Culpepper, Interim CEO and COO of Provectus Biopharmaceuticals, Inc. (NYSE MKT: PVCT), specializes in developing oncology and dermatology therapies, according to the company's website (see here: www.ProvectusBio.com). The video interview was recorded on Wednesday, May 4(th) , 2016, at the Growth Capital Expo MicroCap Investor Conference in Las Vegas, NV.
Click the following link to watch the SNNLive Video Interview on StockNewsNow.com:
Update with Provectus Biopharmaceuticals, Inc. - Discusses Clinical Developments for PV-10, Immunotherapy, Goals and Milestones
You can follow Stock News Now on FACEBOOK, TWITTER, LINKEDIN, YOUTUBE, and STOCKTWITS
Please review important disclosures on our website at: http://stocknewsnow.com/legal.php#disclaimer
About Provectus Biopharmaceuticals, Inc.
Provectus Biopharmaceuticals, Inc. specializes in developing oncology and dermatology therapies. PV-10, its novel investigational drug for cancer, is designed for injection into solid tumors (intralesional administration), thereby reducing potential for systemic side effects. Its oncology focus is on melanoma, breast cancer and cancers of the liver. The Company has received orphan drug designations from the FDA for its melanoma and hepatocellular carcinoma indications. PH-10, its topical investigational drug for dermatology, is undergoing clinical testing for psoriasis and atopic dermatitis. Provectus has completed phase 2 trials of PV-10 as a therapy for metastatic melanoma, and of PH-10 as a topical treatment for atopic dermatitis and psoriasis. Information about these and the Company's other clinical trials, including its current phase 3 study in melanoma, can be found at the NIH registry, www.clinicaltrials.gov. Description of the company and for additional information about Provectus, please visit the Company's website at www.ProvectusBio.com, or contact Porter, LeVay & Rose, Inc.
About StockNewsNow.com
StockNewsNow.com is a microcap financial news portal that features news and insights from the microcap and emerging growth financial community. StockNewsNow.com is a multimedia destination hub for information about microcap and emerging growth public and private companies, market events, news, bulletins, stock quotes, expert commentary and company profiles that feature SNN-produced video like SNNLive CEO video interviews, as well as their latest news and headlines. Users can engage directly and share the information provided through social media.
Follow the companies YOU want to know more about; read and watch content from YOUR favorite microcap, emerging growth financial experts; register to attend financial conferences of YOUR choosing; find microcap and emerging growth financial professionals that YOU may be looking for - all here on StockNewsNow.com.
StockNewsNow.com
info@stocknewsnow.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/stocknewsnowcom-publishes-may-2016-update-snnlive-video-interview-with-provectus-biopharmaceuticals-inc-300269885.html
SOURCE StockNewsNow.com
/Web site: http://www.stocknewsnow.com
(END) Dow Jones Newswires
May 17, 2016 07:55 ET (11:55
StockNewsNow.com Publishes May 2016 Update SNNLive Video Interview with Provectus Biopharmaceuticals, Inc.
50 minutes ago - DJNF
LOS ANGELES, May 17, 2016 /PRNewswire/ -- StockNewsNow.com, The Official MicroCap News Source(TM), today published an SNNLive Video Interview with Peter R. Culpepper, Interim CEO and COO of Provectus Biopharmaceuticals, Inc. (NYSE MKT: PVCT), specializes in developing oncology and dermatology therapies, according to the company's website (see here: www.ProvectusBio.com). The video interview was recorded on Wednesday, May 4(th) , 2016, at the Growth Capital Expo MicroCap Investor Conference in Las Vegas, NV.
Click the following link to watch the SNNLive Video Interview on StockNewsNow.com:
Update with Provectus Biopharmaceuticals, Inc. - Discusses Clinical Developments for PV-10, Immunotherapy, Goals and Milestones
You can follow Stock News Now on FACEBOOK, TWITTER, LINKEDIN, YOUTUBE, and STOCKTWITS
Please review important disclosures on our website at: http://stocknewsnow.com/legal.php#disclaimer
About Provectus Biopharmaceuticals, Inc.
Provectus Biopharmaceuticals, Inc. specializes in developing oncology and dermatology therapies. PV-10, its novel investigational drug for cancer, is designed for injection into solid tumors (intralesional administration), thereby reducing potential for systemic side effects. Its oncology focus is on melanoma, breast cancer and cancers of the liver. The Company has received orphan drug designations from the FDA for its melanoma and hepatocellular carcinoma indications. PH-10, its topical investigational drug for dermatology, is undergoing clinical testing for psoriasis and atopic dermatitis. Provectus has completed phase 2 trials of PV-10 as a therapy for metastatic melanoma, and of PH-10 as a topical treatment for atopic dermatitis and psoriasis. Information about these and the Company's other clinical trials, including its current phase 3 study in melanoma, can be found at the NIH registry, www.clinicaltrials.gov. Description of the company and for additional information about Provectus, please visit the Company's website at www.ProvectusBio.com, or contact Porter, LeVay & Rose, Inc.
About StockNewsNow.com
StockNewsNow.com is a microcap financial news portal that features news and insights from the microcap and emerging growth financial community. StockNewsNow.com is a multimedia destination hub for information about microcap and emerging growth public and private companies, market events, news, bulletins, stock quotes, expert commentary and company profiles that feature SNN-produced video like SNNLive CEO video interviews, as well as their latest news and headlines. Users can engage directly and share the information provided through social media.
Follow the companies YOU want to know more about; read and watch content from YOUR favorite microcap, emerging growth financial experts; register to attend financial conferences of YOUR choosing; find microcap and emerging growth financial professionals that YOU may be looking for - all here on StockNewsNow.com.
StockNewsNow.com
info@stocknewsnow.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/stocknewsnowcom-publishes-may-2016-update-snnlive-video-interview-with-provectus-biopharmaceuticals-inc-300269885.html
SOURCE StockNewsNow.com
/Web site: http://www.stocknewsnow.com
(END) Dow Jones Newswires
May 17, 2016 07:55 ET (11:55
(0)
(0)
I'm in it to win it!
NASDAQ DIP and RIP
Here is the best word that describes what i do here.
Intuitive;
means having the ability to understand or know something without any direct evidence or reasoning process.
I was born with it, I'm truly blessed!
Alway's searching for winners'
NASDAQ DIP and RIP
Here is the best word that describes what i do here.
Intuitive;
means having the ability to understand or know something without any direct evidence or reasoning process.
I was born with it, I'm truly blessed!
Alway's searching for winners'
Scroll down for more posts ▼